iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- PMID: 29540348
- DOI: 10.1182/blood-2017-09-806398
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Abstract
The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.
© 2018 by The American Society of Hematology.
Similar articles
-
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Blood. 2017. PMID: 27895058 Free PMC article. Review.
-
Is MRD eradication a desirable goal in CLL?Best Pract Res Clin Haematol. 2010 Mar;23(1):97-107. doi: 10.1016/j.beha.2010.01.005. Best Pract Res Clin Haematol. 2010. PMID: 20620974 Review.
-
SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia.Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):321-325. doi: 10.1016/j.clml.2019.05.013. Epub 2019 May 29. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31204237 Review.
-
The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.Clin Adv Hematol Oncol. 2020 Jun;18 Suppl 10(6):1-20. Clin Adv Hematol Oncol. 2020. PMID: 33843867
-
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7. Leukemia. 2016. PMID: 26639181 Free PMC article.
Cited by
-
Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia.J Patient Rep Outcomes. 2021 Mar 11;5(1):27. doi: 10.1186/s41687-021-00294-1. J Patient Rep Outcomes. 2021. PMID: 33709202 Free PMC article.
-
Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases.J Clin Exp Hematop. 2024;64(2):152-155. doi: 10.3960/jslrt.24014. J Clin Exp Hematop. 2024. PMID: 38925975 Free PMC article. No abstract available.
-
The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia.Blood. 2023 Jan 26;141(4):369-379. doi: 10.1182/blood.2021014669. Blood. 2023. PMID: 36095842 Free PMC article. Review.
-
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.Pathol Oncol Res. 2022 Sep 21;28:1610659. doi: 10.3389/pore.2022.1610659. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36213161 Free PMC article.
-
Increased Frequency of Circulating Activated FOXP3+ Regulatory T Cell Subset in Patients with Chronic Lymphocytic Leukemia Is Associated with the Estimate of the Size of the Tumor Mass, STAT5 Signaling and Disease Course during Follow-Up of Patients on Therapy.Cancers (Basel). 2024 Sep 22;16(18):3228. doi: 10.3390/cancers16183228. Cancers (Basel). 2024. PMID: 39335199 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical